News headlines about Enzymotec (NASDAQ:ENZY) have been trending somewhat positive this week, Accern Sentiment reports. Accern identifies negative and positive news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Enzymotec earned a daily sentiment score of 0.23 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 44.302532929143 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
A number of brokerages have issued reports on ENZY. BidaskClub cut shares of Enzymotec from a “hold” rating to a “sell” rating in a report on Saturday, January 6th. Wells Fargo & Co raised their price target on shares of Enzymotec from $9.50 to $12.00 and gave the company a “market perform” rating in a research note on Monday, October 30th. Jefferies Group restated a “hold” rating and issued a $11.50 price target on shares of Enzymotec in a research note on Thursday, October 19th. Finally, Zacks Investment Research upgraded shares of Enzymotec from a “strong sell” rating to a “hold” rating in a research note on Tuesday, October 17th. One analyst has rated the stock with a sell rating and four have issued a hold rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $11.75.
Shares of Enzymotec (NASDAQ:ENZY) remained flat at $$11.85 during trading hours on Friday. Enzymotec has a 52 week low of $6.30 and a 52 week high of $12.35. The company has a market capitalization of $277.62, a price-to-earnings ratio of -43.89, a PEG ratio of 3.19 and a beta of 1.22.
COPYRIGHT VIOLATION WARNING: This article was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this article can be accessed at https://www.dispatchtribunal.com/2018/01/13/enzymotec-enzy-earns-media-sentiment-score-of-0-23.html.
Enzymotec Ltd. is a nutritional ingredients and medical foods company. The Company’s technologies, research expertise and clinical validation process enables it to develop solutions across a range of products. The Company operates in two segments: Nutrition segment and VAYA Pharma segment. Both of the Company’s segments offer a range of products that leverage its lipid-related offerings.
Receive News & Ratings for Enzymotec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzymotec and related companies with MarketBeat.com's FREE daily email newsletter.